Science is a startup company that develops technologies for a range of serious unmet medical needs.
Science is a startup company that develops technologies for a range of serious unmet medical needs.
Therapeutic Devices📍 Alameda, CAFounded 2021
Current Valuation
$1.5B
as of 2026-Q1
UNICORN
QL Price
$1.5B
0% vs last round
QuantLogix's current estimate for Science, published 2026-09-09 — in line with the last disclosed round of $1.5B (2026-Q1).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round
$1.5B
2026-Q1
weight 0.74
Secondary market print
$1.5B
2026-06-27
weight 0.64
How this price has held up
No round has priced for Science since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-09 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Science, 2026-09-09 (9f0338e8812c3cbc).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Science going public?
No. Science is private and has not filed to go public. There is no S-1 on file.
What is Science's valuation in 2026?
Science is valued at $1.5B as of 2026-Q1, set by its Series C ($230M, Mar 2026). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Science filed an S-1?
No public S-1 is on file for Science.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2021
HQ
Alameda, CA
Employees
150
Total Raised
$519.6M
Last Round
Series C — $230M (Mar 2026)
IPO Status
private
Fundraising Status
Series C · $230M · 6 mo ago
privateTotal raised $519.6M
Secondary Market
Implied price / share
$4.76
Open interest
2
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series C
$230M
Mar 2026
—
$1.5B
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Science — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-03. Re-checked weekly.
Talent Signal
Hiring trend
● First snapshot
trend accrues with monthly sweeps
Open roles
9
via careers page
Product-build share
67%
engineering, research, product, design
Trajectory
steady
heavy product build — 67% of open roles are product-building functions (engineering/research/product) — 4 of 9 open roles are engineering.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Neural Engineering[MEMS Production MEMS process development and wafer fabrication \\[Neural Engineering Build with our neural engineering toolkit \\The future of neural engineering isn't building itselfScience Corporation is a clinical-stage medical technology company[Neural Engineering](https://science.xyz/services/foundry/neural-engineering)
Counted from Science's live job board as of 2026-08-17; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
MedicalBiotechnologyProduct Research
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2026-Q1. Refreshed quarterly.